Search results
Results from the WOW.Com Content Network
The ERT has been suggested as a predictor for the level of success of the use of endocrine therapy in cancer treatment. Many of the endocrine therapies for breast cancer treatments involve the use of selective estrogen receptor modulators (SERMs). SERMs, such as tamoxifen, are ER antagonists in breast tissue. Estrogen receptor tests are used in ...
Genetic polymorphisms in the gene encoding the ERα have been associated with breast cancer in women, gynecomastia in men [23] [24] and dysmenorrhea. [ 25 ] In patients with breast cancer, mutations in the gene encoding ERα (ESR1) have been associated with resistance to endocrine therapy, especially aromatase inhibitors .
The Oncotype DX® breast cancer assay is one such test used to predict the likelihood of breast cancer recurrence. This test is intended for women with early-stage (Stage I or II), node-negative, estrogen receptor -positive (ER+) invasive breast cancer who will be treated with hormone therapy .
Tumor markers can be molecules that are produced in higher amounts by cancer cells than normal cells, but can also be produced by other cells from a reaction with the cancer. [2] The markers can't be used to give patients a diagnosis but can be compared with the result of other tests like biopsy or imaging. [2]
There are two different forms of the estrogen receptor, usually referred to as α and β, each encoded by a separate gene (ESR1 and ESR2, respectively).Hormone-activated estrogen receptors form dimers, and, since the two forms are coexpressed in many cell types, the receptors may form ERα (αα) or ERβ (ββ) homodimers or ERαβ (αβ) heterodimers. [3]
[24] [25] ERβ is also highly expressed in normal breast epithelium, although its expression declines with cancer progression. [26] ERβ is expressed in all subtypes of breast cancer. [ 27 ] Controversy regarding ERβ protein expression has hindered study of ERβ, but highly sensitive monoclonal antibodies have been produced and well-validated ...
MammaPrint is a prognostic and predictive diagnostic test for early stage breast cancer patients that assess the risk that a tumor will metastasize to other parts of the body. [1] It gives a binary result, high-risk or low-risk classification , and helps physicians determine whether or not a patient will benefit from chemotherapy .
ER-positive is one of the Receptor statuses identified in the classification of breast cancer.Receptor status was traditionally considered by reviewing each individual receptor (ER, PR, her2) in turn, but newer approaches look at these together, along with the tumor grade, to categorize breast cancer into several conceptual molecular classes [1] that have different prognoses [2] and may have ...